Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.

Producción científica: Review articlerevisión exhaustiva

4 Citas (Scopus)

Resumen

Tumor necrosis factor-alpha (TNF-alpha) antagonists were unexpectedly found to have no beneficial effects in moderate-to-severe heart failure in two large randomized clinical trials. In certain doses, the agents were found to be harmful. These results have important implications for rheumatoid arthritis (RA). Patients with the disease have an increased risk for developing cardiovascular co-morbidity, including heart failure. Because of the beneficial effect of the TNF-alpha antagonists in the management of RA, these agents have gained widespread use. Rheumatologists and other physicians who provide care for RA are thus likely to encounter candidates for anti-TNF-alpha therapy who have overt or subclinical heart failure. Although data are currently not sufficient to support evidence-based recommendations, it is possible to make reasonable suggestions to guide clinical practice.

Idioma originalEnglish (US)
Páginas (desde-hasta)395-399
Número de páginas5
PublicaciónCurrent rheumatology reports
Volumen7
N.º5
DOI
EstadoPublished - oct 2005

ASJC Scopus subject areas

  • Rheumatology

Huella

Profundice en los temas de investigación de 'Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.'. En conjunto forman una huella única.

Citar esto